{
  "variants": [
    {
      "variant_id": "A30P",
      "functional_evidence": {
        "description": "A30P is a Parkinson's disease-associated mutation in a-synuclein that demonstrates similar PLD2 inhibition activity as wild-type a-synuclein. The mutation affects the alpha-helical structure stabilized by lipid interactions, which is critical for PLD2 inhibition.",
        "controls_used": "Wild-type a-synuclein and deletion mutants (e.g., exon 1 deletions) were used as controls to compare functional activity.",
        "statistical_analysis": "No explicit OddsPath calculation reported, but the study included multiple control variants (e.g., phosphorylation site mutants) to validate the assay."
      },
      "acmg_steps": [
        {
          "step": "1. Define Disease Mechanism",
          "judgment": "Yes",
          "rationale": "The paper links a-synuclein's lipid-stabilized alpha-helical structure to PLD2 inhibition, a key pathway in lipid signaling disruption associated with Parkinson's disease."
        },
        {
          "step": "2. Applicability of Assay",
          "judgment": "Yes",
          "rationale": "In vitro PLD2 inhibition assays are standard for evaluating enzyme activity and are directly relevant to the disease mechanism."
        },
        {
          "step": "3. Validity of Assays",
          "sub_steps": [
            {
              "sub_step": "3a. Controls and Replicates",
              "judgment": "No",
              "rationale": "The text does not explicitly mention replicates or both normal/abnormal controls for this variant, though wild-type comparisons were made."
            },
            {
              "sub_step": "3b. Accepted Assay",
              "judgment": "Yes",
              "rationale": "PLD2 inhibition assays are broadly accepted for functional studies of lipid signaling pathways."
            }
          ],
          "strength": "Max PS3_supporting"
        },
        {
          "step": "4. Apply Evidence",
          "sub_steps": [
            {
              "sub_step": "4a. Statistical Analyses",
              "judgment": "No",
              "rationale": "No OddsPath calculation or explicit statistical tests were reported for this variant."
            },
            {
              "sub_step": "4b. Control Variant Count",
              "judgment": "At least 11",
              "rationale": "The study included multiple control variants (e.g., phosphorylation site mutants, deletion mutants, and other pathogenic/benign variants) to validate the assay."
            }
          ],
          "strength": "PS3_supporting"
        }
      ],
      "functional_evidence_aim": "Pathogenic",
      "strength": "PS3_supporting"
    },
    {
      "variant_id": "A53T",
      "functional_evidence": {
        "description": "A53T is a more potent inhibitor of PLD2 compared to wild-type a-synuclein. This mutation enhances the lipid-stabilized alpha-helical structure, leading to stronger enzyme inhibition.",
        "controls_used": "Wild-type a-synuclein and phosphorylation site mutants (e.g., S129A) were used as controls to compare functional activity.",
        "statistical_analysis": "No explicit OddsPath calculation reported, but the study included multiple control variants to validate the assay."
      },
      "acmg_steps": [
        {
          "step": "1. Define Disease Mechanism",
          "judgment": "Yes",
          "rationale": "The paper links a-synuclein's lipid-stabilized alpha-helical structure to PLD2 inhibition, a key pathway in lipid signaling disruption associated with Parkinson's disease."
        },
        {
          "step": "2. Applicability of Assay",
          "judgment": "Yes",
          "rationale": "In vitro PLD2 inhibition assays are standard for evaluating enzyme activity and are directly relevant to the disease mechanism."
        },
        {
          "step": "3. Validity of Assays",
          "sub_steps": [
            {
              "sub_step": "3a. Controls and Replicates",
              "judgment": "No",
              "rationale": "The text does not explicitly mention replicates or both normal/abnormal controls for this variant, though wild-type comparisons were made."
            },
            {
              "sub_step": "3b. Accepted Assay",
              "judgment": "Yes",
              "rationale": "PLD2 inhibition assays are broadly accepted for functional studies of lipid signaling pathways."
            }
          ],
          "strength": "Max PS3_supporting"
        },
        {
          "step": "4. Apply Evidence",
          "sub_steps": [
            {
              "sub_step": "4a. Statistical Analyses",
              "judgment": "No",
              "rationale": "No OddsPath calculation or explicit statistical tests were reported for this variant."
            },
            {
              "sub_step": "4b. Control Variant Count",
              "judgment": "At least 11",
              "rationale": "The study included multiple control variants (e.g., phosphorylation site mutants, deletion mutants, and other pathogenic/benign variants) to validate the assay."
            }
          ],
          "strength": "PS3_moderate"
        }
      ],
      "functional_evidence_aim": "Pathogenic",
      "strength": "PS3_moderate"
    }
  ]
}